TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Instagram Outage Disrupts Thousands of U.S. Users 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
LA JOLLA, Calif., Nov. 01, 2016 -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company at two upcoming investor conferences.
- Credit Suisse 25th Annual Healthcare Conference, Scottsdale, AZ, November 8, 2016 at 3:30 p.m. MST (2:30 p.m. PST)
- Stifel 2016 Healthcare Conference, New York, November 15, 2016 at 8:00 a.m. EST (5:00 a.m. PST)
A live audio webcast and replay of each presentation will be available in the Investors section of Kura Oncology's website at www.kuraoncology.com
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. The preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL program. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849-5375 [email protected]
